6533b82cfe1ef96bd1290057

RESEARCH PRODUCT

SYNTHESIS, CHARACTERIZATION AND IN VITRO CYTOTOXICITY STUDIES OF A MACROMOLECULAR CONJUGATE OF PACLITAXEL BEARING OXYTOCIN AS TARGETING MOIETY.

Gaetano GiammonaDomenico SchillaciMonica CampisiGennara CavallaroLaura Maniscalco

subject

Time FactorsChemistry PharmaceuticalDrug CompoundingpolyaspartamidePharmaceutical ScienceBreast NeoplasmsPolyethylene Glycolschemistry.chemical_compoundpaclitaxelDrug StabilityCell Line TumoroxytocinHumansMoietyProdrugsbioconjugateCytotoxicityCell ProliferationDrug CarriersDose-Response Relationship DrugMolecular StructureHydrolysisdrug targetingGeneral MedicineHydrogen-Ion ConcentrationAntineoplastic Agents PhytogenicOxytocin receptorIn vitroSolubilityPaclitaxelchemistryBiochemistryTargeted drug deliveryReceptors OxytocinDelayed-Action PreparationsFemalePeptidesDrug carrierBiotechnologyConjugate

description

The present study describes the experimental synthetic procedure and the characterization of a new polyaspartamide macromolecular prodrug of paclitaxel, bearing oxytocin residues as targeting moieties. In vitro stability studies of bioconjugate, performed in media mimicking biological fluids (buffer solutions at pH 7.4 and 5.5) and in human plasma, evidenced the high stability of the targeting portion (oxytocin)-polymer linkage and the ability of this conjugate to release linked paclitaxel in a prolonged way in plasma. Moreover, preliminary in vitro antiproliferative studies, carried out on MCF-7 cells, that are oxytocin receptor positive cells, showed that the polymeric conjugate has the same cell growing inhibition ability of free drug.

yearjournalcountryeditionlanguage
2007-05-01
10.1016/j.ejpb.2006.10.013http://hdl.handle.net/10447/25479